Daklinza
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Daclatasvir
- Made by
- Bristol-Myers Squibb Pharma EEIG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults (see sections 4.2, 4.4 and 5.1). For HCV genotype specific activity, see sections 4.4 and 5.1.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
NetherlandsNo exact match for this strength and form
Details
| Made by | Bristol-Myers Squibb Pharma EEIG |
|---|---|
| Active substance | Daclatasvir |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J05AP07 · Antibiotics, antivirals and antifungals taken into the body |
| Authorised on | 2014-08-22 |
| Last updated by the regulator | 2019-08-30 |
| EMA product number | EMEA/H/C/003768 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).